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Abstract  
 
Interactive learning, particularly between firms and public research organizations (PRO), nurtures the 
dynamics of systems of innovation. Limited interaction contributes to explain poor performance in 
R&D and ultimately, in innovation by developing countries. But why this is so? Based on evidence 
from the pharmaceutical industry in Mexico, this paper identifies some determinants of PRO-industry 
interaction for pharmaceutical R&D. Particular attention is granted to factors hindering such 
interactions; arguably the barriers differ throughout the diverse stages of the R&D process. The paper 
decomposes the Research and Development processes, thus it is possible to identify determinants to 
interactions in each of those instances. Drug development is further split in two stages: clinical 
research and drug manufacturing. The analysis indicates that macroeconomic and business 
environments, firms’ strategies, ethical considerations, incentives and perceptions of PRO-industry 
interaction among the agents in the system, support/hinder interactivity in pharmaceutical R&D.  
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1. Introduction 
 
Learning and innovation are predominantly interactive, socially embedded processes that take place 
within particular socioeconomic, institutional and cultural contexts (Freeman 1995; Lundvall et al 
2002). Innovation is a complex process that involves strategic choices, concurrent (inter) actions and 
knowledge flows among agents within systems of innovation. Agents are heterogeneous, from firms 
to knowledge producer and research organizations, intermediary actors, regulatory and policy making 
bodies, and institutions -as laws, rules, norms, and routines (Edquist 2004). Distinct agents face and 
respond differently to diverse incentives and obstacles to innovation.  
 
Notwithstanding the heterogeneous ecology characteristic of systems of innovation, the literature 
recognises firms as being responsible for most innovations (Nelson and Winter 1982). And yet the 
systemic nature of learning and innovation implies that no matter how competent individual firms are 
in a given area, such competences are bounded; abilities to carry out search processes are limited 
(Cohen and Levinthal 1989 and 1990). Firms face problems in performing innovations which require 
knowledge outside their immediate area of expertise; firms must be able to interact with and gain 
access to diverse knowledge sources (Arora et al 2001; Cohen, et al., 2002).  
 
Research strides to understand the determinants, benefits and policy interventions supporting 
interactivity within systems of innovation. Interactions between universities and research centres, 
hereafter public research organizations (PRO), and firms play prominent roles in the literature 
(Freeman 1995; Mazzoleni and Nelson 2007; Eom and Lee, 2009). For instance research on national 
systems of innovation (NSI) and on successful catching up processes suggests that interactivity within 
NSI contributes to advance a country’s scientific, technological and innovation capabilities, and 
thereby the prospects for socioeconomic development. PRO-industry interactions need to be flexible 
over time; they differ across knowledge fields (Monjon and Waelbroeck, 2003; Welsh et al, 2008).  
 
PRO-industry interactions recognise that both firms and PRO produce and use knowledge. 
Interactivity involves knowledge flows in both directions in ways such that promote virtuous circles 
in knowledge production, diffusion and use. Interactions are dynamic, changing overtime as agents in 
the system and countries develop. The dynamics of PRO-industry interactions reflects the co-
evolution of factors, such as research capabilities of PRO on the one hand, and absorptive and 
technological capacities within firms on the other. A firm requires complementary in-house 
technological efforts to absorb knowledge acquired through external collaborations (Cohen and 
Levinthal 1989 and 1990; Santamaría et.al, 2009).  
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Laursen and Salter (2004) illustrate the distinct steering power of firms, as the agent at the centre of 
the NSI. The authors showed that firms with "open" search strategies more likely draw from 
universities to underpin innovative activities. Likewise R&D intensity is a strong driver of linkages 
with university knowledge during innovation. As firms grow, they increase capabilities and 
inclination to draw from university research. The authors concluded that although structural factors 
bear on a firm's use of university knowledge and information, additional factors such as business 
strategies and managerial choices matter as well. 
 
In this context, one of the most disquieting weaknesses of Mexico’s developing NSI is that low levels 
of R&D accompany limited or poor interactions within such system (Cimoli 2000; Cimoli and 
Constantino 2000; Dutrénit et al, 2010); although some firms in the country benefit from contacts 
with PRO there is little fruitful interaction (Dutrénit et al, 2010). Casas (2001, 2005) indicate that 
firms in Mexico rely, almost exclusively, on internal learning efforts to fulfil knowledge 
requirements. Successful PRO-industry linkages often limit to a handful of firms in specific sectors, 
including metalworking, health, chemicals and pharmaceuticals. Recent policy initiatives to 
strengthen PRO-industry interactions, and enhanced pressures for academic organisations to identify 
and leverage new sources of funding have had limited success (FCCT 2006).  
 
Whereas available research explores and maps PRO-industry interactions in developing NSI, we still 
know little about factors hindering such interactions. Some studies confirm that sector characteristics 
matter as determinants of PRO-industry interactions (Cohen, et al., 2002; Laursen and Salter, 2004; 
Torres et al, 2010), more research is needed approaching specific sectors in developing countries. 
Thus one can better appreciate why dynamic PRO-industry interactions remain limited in countries 
such as Mexico, or how to overcome barriers to interaction. Further research should also provide a 
more balanced view of the determinants and incentives to PRO-industry interactions in relevant 
sectors; hence it is possible to inform public policies intended to increase interactivity and thereby 
improved performance of developing NSI.  
 
This paper argues that PRO-industry interactions underpinning pharmaceutical R&D in Mexico 
respond to several, somewhat reinforcing sources, which reflect general country conditions and 
industry specific factors. Determinants, and particularly barriers to interaction, differ across the 
distinct stages of the innovation process, notably R&D. In addressing these issues, this paper proceeds 
as follows: Section 2 presents the data and data sources. The analysis builds on qualitative data 
collected through interviews with firms, PRO and policy makers linked to the pharmaceutical industry 
in Mexico. Section 3 characterizes recent trends in the global pharmaceutical industry; the focus is on 
the prospects for developing countries. A description of the pharmaceutical innovation process is also 
provided. The section ends with a characterization of pharmaceuticals in Mexico. Section 4 discusses 
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some general trends in PRO-industry interactions in Mexico. Section 5 contains the core of the 
analysis; it documents determinants to PRO-industry interactions for pharmaceutical R&D in Mexico. 
Section 6 concludes.  
 
2. The data  
 
This paper builds mostly on qualitative data about pharmaceutical firms in Mexico. Primary data were 
collected through semi-structured interviews carried out in February-August and October-December, 
2007, and a final round late in 2008. Informants included representatives of multinational affiliates 
and Mexican pharmaceutical firms–General directors, medical directors, R&D managers, 
development analysts; and the main local trade organisations: National Association of the 
Pharmaceutical Industry (CANIFARMA for its acronym in Spanish), the Mexican Association of the 
Industry for Pharmaceutical Research (AMIIF for its acronym in Spanish) and the Mexican 
Association of Drug Manufacturers (ANAFAM for its acronym in Spanish). Membership overlaps 
across these three organisations but CANIFARMA is the largest of them; its members account for 85 
percent worth of the local private drug market. AMIIF conglomerates the 30 or so multinational 
affiliates more active in pharmaceutical research, mainly clinical trials, in Mexico. 
 
In order to identify the actual number of pharmaceutical firms in Mexico we followed Secretaría de 
Salud (2005) who estimated that in 2005, 200 such firms operated in Mexico. This study approached 
140 firms, mostly through CANIFARMA. In total 40 firms replied to our invitation-response rate 28.6 
percent-, but only 22 provided usable data. The 18 remaining firms were unwilling to participate in 
the study; reasons for this included internal policies preventing them to do so, “ethical reasons” or 
difficulties to provide confidential information. Some firms required an official request from the local 
regulatory agency; reticence of individuals to provide information was due to strict confidentiality 
agreements signed with the company.  
 
The interviews took an hour long on average, in the majority of cases were audio-taped and partially 
transcribed afterwards. For reasons of an explicit commitment to confidentiality, identity of 
informants and firms remains anonymous; we refer to them as Firm 01 through Firm 22; Trade1 
through Trade3; and InsH1 through InsH3--see Annex 1. The interviews informed about the extent to 
which firms conduct pharmaceutical R&D in Mexico, activities included and reasons to do or not to 
do so. Emphasis was put on learning about the main opportunities/challenges derived from the general 
conditions for R&D in the country: research infrastructure, availability of human resources, the match 
between the research agendas of firms and PROs, and so on. Additional questions explored the firm’s 
publishing practices, the relationship with regulatory agencies and so on. Interviewees were prompted 
with claims by previous interviewees in order to crosscheck information. 
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Additional interviews took place at the Mexican regulatory agency, the Federal Commission for the 
Protection against Health and Sanitary Risks (COFEPRIS for its acronym in Spanish); the 
Coordinating Commission of the National Institutes of Health and Specialty Hospitals (CCINSHAE 
for its acronym in Spanish), and the Mexican Institute of Health and Social Security (IMSS for its 
acronym in Spanish). In all these cases the questions were similar to those posed to firms but 
rephrased as necessary to capture the opinion of these organisations.  
 
Three official notes were obtained from COFEPRIS following requests through the Mexican 
government’s portal for transparency and access to information (IFAI for its acronym in Spanish). 
Attendance to a specialized seminar on clinical research, LamtechInstitute (2007), informed about 
such activities in Mexico and Latin America as well.  
 
Additional data stems from two surveys, conducted during 2008, on the nature of PRO-industry 
interactions in Mexico. The surveys took the individual as the unit of analysis. One of them targeted 
R&D and product development managers within firms. The working sample consists of 387 
questionnaires out of a target population of 1200 firms; response rate of 32.6 percent. The 
participating firms split in two groups: first those who have benefited from CONACYT’s research 
funds. A second group includes firms that have not received public funds for R&D. The control group 
took into account the size, sector and location characteristics of the first group of firms. Both groups 
include collaborative and non-collaborative firms. The distribution of firms by size, sectors and 
regions obtained in the received questionnaires are consistent between the two groups of firms.  
 
An additional survey focused on researchers at PROs. An email questionnaire was sent to 10,100 
researchers from the National Researchers System1 (SNI for its name in Spanish), but the response 
rate was very low. We turned to a shortlist of 2,043 researchers provided by the Council for Science 
and Technology in Mexico (CONACYT), based on those knowledge fields that are most active in 
applying for public grants. We complemented this list with 1,380 researchers working in engineering 
departments of the main PROs in Mexico. Thus the survey included researchers independent from the 
SNI but that link with firms. The response rate was 14% for a working sample of 461 questionnaires. 
This paper discusses some general findings from such surveys; Dutrénit, et al., (2010) present more 
                                                 
1 The SNI is one of the instruments supporting S&T activities with the longest tradition in Mexico. Since 
inception in 1984, the system promotes the formation, development and consolidation of a critical mass of 
researchers at the highest level, mostly within the public system of higher education and research. Member 
researchers receive both pecuniary (a monthly compensation) and non-pecuniary stimulus (status and 
recognition) based on the productivity and quality of their research.  
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detailed results.  
 
Secondary sources of data included academic and industry literature and online datasets. Statistical 
data stem from the latest national innovation survey (Encuesta sobre Investigación y Desarrollo de 
Tecnología –ESIDET) carried out by CONACYT in Mexico in 2006 (CONACYT 2007). This paper 
used information about the pharmaceutical industry only. Secondary data sources helped to validate 
information obtained through interviews.  
 
3. The pharmaceutical industry 
 
3.1. The innovation process  
 
Pharmaceutical innovation comprises four somewhat overlapping instances whose length and costs 
depend on legal, ethical, scientific and economic factors (Figure 1): (1) basic research leading to 
identification of new molecular targets, “New Chemical Entities (NCEs),”2 and pre-clinical studies;3 
(2) clinical research that aims to test and eventually, certify efficacy, safety and overall socio- and 
techno-economic viability of mass production of new drugs or medical devices (Zivin 2000); (3) 
regulatory processes governing R&D, registry and commercialization of drugs; important regulatory 
events include: filing/obtaining patents, applications to commence clinical trials of investigational 
new drugs (IND), and authorization to market new drugs (NDA); and (4) manufacturing, marketing 
and product life-cycle support of existing drugs. In the case of new drug development this stage 
begins with clinical research and gears to assess economic and industrial viability of the potential new 
drugs. Generics drugs development, and improved drug manufacturing processes also occur at this 
point; a major difference is that clinical testing here seeks to prove interchangeability with the 
innovator drug. The model of pharmaceutical innovation in Figure 1 also applies to Mexico (personal 
communication, COFEPRIS, 8 January 2006). 
 
Developing countries such as Mexico contribute mostly to the advanced stages of the pharmaceutical 
innovation cycle as depicted in figure 1. In other words, during their contribution is during clinical 
trials, or in the life-cycle support of existing pharmaceutical products; the latter includes development 
of generics drugs. For the sake of comprehensiveness of the analysis, this paper looks at two broad 
dimensions of pharmaceutical innovation: Research and Development. The latter splits in two 
                                                 
2 NCEs are totally new drugs, which in most cases represent significant therapeutic advances. 
3 Pre-clinical studies in animals or other models assess toxicity and other pharmacokinetic properties of 
prospective NCEs before tests in humans can begin. Similar tests are performed in humans during clinical 
research (Zivin 2000). 
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instances namely, clinical research and generics drug manufacturing. 
 
 
Figure 1: Schematic representation of pharmaceutical innovation process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes: IND: Investigational New Drug; NDA: New Drug Application. 
Source: Santiago (2010) 
 
 
3.2. Global dynamics 
 
The global pharmaceutical industry stands out for its socio-economic, health and ethical implications; 
intensive R&D efforts characterize it as a highly science-based industry. Innovation conditions 
strongly success in the industry, particularly at times of increased competition from generic 
manufacturers and a relatively slow pace of new drug innovation. Pharmaceuticals systematically rank 
among the top R&D expending sectors throughout the developed world (NSF 2008). Continuous 
exploration for technological opportunities and innovation is critical for competitiveness and success 
of global pharmaceutical firms. Competition in the industry is such that internal technological efforts 
are insufficient to respond, in a timely manner, to current market dynamics. Mergers and acquisitions, 
outsourcing and off-shoring, together with joint performance of R&D increasingly guide business 
strategies of global firms. Interactions with PROs seek to tap into external knowledge and expertise, 
reduce cost and speed up new drug development (Piachaud 2002; Crossley 2004; Santiago 2009).  
 
Developing countries are expected to influence significantly future developments in the global 
pharmaceutical industry. By the year 2013, 17 high-growth emerging pharmaceutical markets will 
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contribute 48 percent of annual market growth–up from 37 percent in 2009; in aggregate terms such 
countries will expand by US$90 billion during 2009-13 (Gatyas and Savage 2010). China, Brazil, 
India, Russia and to a lesser extent Venezuela, Poland, Argentina, Turkey, Mexico, Vietnam, South 
Africa, Thailand, Indonesia, Romania, Egypt, Pakistan and the Ukraine are emerging economies with 
potential to drive the industry in the coming years. According to IMS-Health (2009) factors explaining 
these positive trends in developing countries include growing government expenditure in healthcare 
and raising demand for innovative medicines. Although the technological dynamism of firms in 
catching up countries generally lags behind that of large multinationals, R&D remains core for 
success. The major difference is that, in general, R&D in developing countries underpins incremental 
innovations (Cardinal and Hatfield 2000; Kim 1997). 
 
3.3. Pharmaceuticals in Mexico 
 
Mexico ranks among the world's largest pharmaceutical markets, and is the second in Latin America. 
Together with Brazil, Argentina and Venezuela, the country accounts for more than 80% of total sales 
in Latin America (Secretaría de Salud 2005). At the end of 2008 retail sales in the Mexican 
pharmaceutical market amounted to US$8.6 billion, up by two percent relative to 2007. Local 
infrastructure to manufacture pharmaceuticals is among the most modern in the world, often 
complying with US Food and Drug Administration (FDA) standards of quality and safety of products, 
facilities and personnel (Trade2 and firm02).  
 
According to Guzmán (2005) and Secretaría de Salud (2005) such factors as local consumption and its 
ample integration to international markets give Mexico potential to become an important centre for 
pharmaceutical innovation. Unfortunately this potential remains largely unrealized; major bottlenecks 
result from an unsuitable environment to carry out R&D, gaps in health and sanitary regulations 
among other factors (Santiago 2010b; Secretaría de Salud 2005). Plans to effectively promote 
development of the industry are absent (Firms 05, 06 and 11 and Trade1). Additional gaps result from 
high cost of basic infrastructure and energy; tight price controls, macroeconomic risks and uncertain 
policy environment (Secretaría de Salud 2005).  
 
In 2005 total innovation-related expenditure by the pharmaceutical industry in Mexico was US$132-
148 million (CONACYT 2007). Investment in machinery and equipment on the one hand, and R&D 
on the other, are the two main components with combined shares of 80 percent of total expenditure. 
Nevertheless R&D represents the largest component of innovation-related expenditure, 45 percent. 
Investment in industrial design or prototype plants is also relevant for the industry. By contrast 
acquisition of software and other external technologies, and expenditure on innovation-relevant 
training occupy minor proportions in total investment in innovation-related activities. 
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Pharmaceutical innovation in Mexico characterizes by limited performance of basic research or drug 
discovery and growing activity in clinical research. Most technological contributions are in the 
manufacturing or post-marketing stage of the pharmaceutical innovation cycle, in the form of 
incremental innovations namely, novel analytic methods, drug delivery systems, new applications or 
reformulation of existing molecules, new dosage forms, vaccines and generics drugs (Trade1 and 
Firms 04 and 05). Firms create new excipients or recombinations of them (Firms 05 and 11, Trade1).  
 
Pharmaceutical firms in Mexico replicate existing drug manufacturing processes in order to obtain 
marketing approval by local authorities (Firms 07, 11 and 13). At advanced stages of technological 
development firms seek to enhance quality of existing drugs. Some local firms, such as Silanes, 
Probiomed, Grupo Techsphere and Alpharma, have attained or are developing capacity to research 
NCEs based mostly on biotechnology techniques and closer interaction with public and private 
research organisations in Mexico and abroad. Biotechnology is a viable though still expensive way to 
build in-house R&D capabilities (Firms 03, 06 and 10).  
 
According to CONACYT (2007), in 2004 and 2005, 59.1 percent of pharmaceutical firms in Mexico 
performed in house R&D, the majority of which, 94.8 percent, obtained some kind of result (Table 1). 
By far product innovations are the most frequent. Firms that perform R&D with some kind of results 
(181) introduced, on average, 16.8 new or improved pharmaceutical products. The number of firms 
introducing some new or improved process is considerably smaller (75); on average firms introduced 
some 15.7 process innovations.  
 
In Mexico most pharmaceutical innovations are new to the country or new to the firm. In general 
firms tap into available knowledge to adapt products and/or processes to the local market. Few firms 
have produced drugs which are completely new to the world (Firms 04, 10, 11 and 14); these are 
mostly recombination of existing drugs. Sales revenue makes little distinction between new and 
improved products; new products represent 53.0 percent of total sales. The figure contrasts 
significantly with the sales of innovative products by the whole of the manufacturing sector, up to two 
thirds of total sales. Although pharmaceuticals record a larger R&D intensity in terms of sales, sales 
revenue from new or improved products is lower than manufacturing as a whole. 
 
The larger number of pharmaceutical patents taken in Mexico is by multinationals; this supports 
marketing of innovative drugs, particularly to serve the private market. By contrast low patenting 
activity of local agents reflects the limited learning activities carried out in the country. According to 
Guzmán (2005) the bulk of pharmaceutical patents taken by Mexican agents correspond to individuals 
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or research organisations; only a minor share are taken by domestic firms and traduced into 
marketable products.  
 
 
Table 1. Innovative performance of the Mexican pharmaceutical industry, 2004-2005 
 Pharmaceuticals Manufacturing  Pharmaceuticals Manufacturing
Total firms 323 16398 Distribution of sales by novelty of product (%) 
Carried out R&D1/  New 24.2 31.8 
Yes 191 4,090 Improved 28.8 36.4 
With results 181 4,040 No change 47.0 31.8 
No 132 12,307 Total 100 100 
Results from R&D Patents 
Products 3,043 35,471  Applied Granted 
Yes1/ 181 3,891 Mexico 64 22 
% of total firms 56.3 23.7 Abroad 56 11 
Processes 1,178 9,444 Total 119 33 
Yes1/ 75 2,001 Linkage activity in pharmaceuticals1/ 
% of total firms 23.2 12.2  Product/Services Process 
Innovations by degree of novelty (per cent) In house 138 69 
Firm Country World Research Centres 10 4 
21.4 77.6 1.0 Universities 15 0 
   Other firm 18 2 
   Total 181 75 
Notes: 1/ Number of firms 
Source: Santiago (2010) with information from CONACYT (2007) 
 
 
4. PRO-industry interactions in Mexico 
 
4.1. National context 
 
Interactivity within the Mexican NSI is limited. CONACYT (2007) documents that in 2005 only two 
percent of innovation projects carried out by firms involved PRO-collaboration. In that same year the 
share of university R&D financed by the industry was equivalent to one percent of total R&D by 
Mexican universities; the figure contrasts significantly with the OECD’s average of 6.1 percent.  
 
Notwithstanding the limited interactivity in the Mexican NSI, the two surveys on PRO-industry 
linkages described in Section 2 revealed that such interactions are stronger than usually expected; 
firms link with universities for consultancy services but also for some joint R&D. Nevertheless 
suppliers and competitors persist as being the main information/knowledge sources for firms. These 
findings mirror those of Cohen, et al., (2002), Laursen and Salter (2004), Eom and Lee (2009). 
Formal and informal modes of interaction are multiple and complementary; however human resources 
hiring and training, and research-based collaborations are the most important.  
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As expected by the knowledge-based theory of the firm PRO-industry interactions sustain activities 
either that increase a firm’s technological capabilities, or that complement such capabilities (Grant 
1996). The importance of PRO-industry interactions augments with the complexity in the expected 
innovation, the more novel the innovation the more dynamic the PRO-industry linkages. Human 
resources mobility facilitates knowledge flows between firms and PRO. Geographic proximity plays 
also important role as determinant of collaboration.  
 
4.2. PRO-industry interactions in pharmaceuticals 
 
Table 1 shows that in Mexico three quarters of firms that introduced some product innovations did so 
without interacting with other agents. The disconnection is more evident in the case of linkages 
underpinning process innovations, only a minor share of innovative projects involved cooperation. In 
fact linkages with universities were of little or no relevance at all for process innovations. CONACYT 
has undertaken some corrective actions to promote interactivity in the Mexican NSI, namely: adoption 
of fiscal incentives to R&D, and creation of sectoral and regional research funds. CONACYT funds 
projects jointly performed by firms and other organisations. In 2006 investment in such projects added 
up to MX$3,999.8 million (US$366.9 million) (Table 2); 481 firms participated in 1,616 projects. The 
two latter figures more than tripled compared to 2001. Notwithstanding these efforts, interactivity 
remains modest (FCCT 2006). 
 
 
Table 2. CONACYT’s investment in projects involving interactions of firms and other agents, 2001-2006 
 2001 2002 2003 2004 2005 2006 
Pharmaceutical industry 
Firms1/ 9 16 27 35 50 48
Projects1/ 31 95 132 202 278 273
Investment2/ 3.1  3.2 5.7 11.6 17.9 29.0 
Inv/project3/ 100.8  33.2 43.1 57.2 64.3 106.1 
Share in total 
Firms1/ 6.3 7.4 11.4 9.8 8.2 10.0
Projects1/ 6.1 11.5 15.1 15.4 13.3 16.9
Investment2/ 6.5 5.0 10.1 9.5 6.2 7.9
Total   
Firms1/ 142 216 236 357 608 481
Projects1/ 506 824 873 1308 2083 1616
Inv/project3/ 95.2 76.1 64.8 93.0 137.4 227.1
Notes: 1/ Number; 2/US$ million, 2006=100; 3/US$ Thousand  
Source: Author with information from CONACYT 
 
 
Participation of pharmaceutical firms in CONACYT-sponsored R&D funds increased considerably 
between 2001 and 2006, from nine to 48 firms. This notwithstanding, the figures suggest 
inconsistency in resource allocation. The average allocation per project was constant between 2002 
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and 2006. More detailed information about the number of applicants and corresponding funding 
requirements is missing; hence it is difficult to see how the base of firms with capacity to apply for 
public grants is changing over time. Although the number of both pharmaceutical firms and projects 
has increased, investment per project has hardly followed pace. The number of pharmaceutical firms 
supported by CONACYT is a minor fraction, about ten percent, of those that could potentially 
participate. We now explore some factors likely to explain the low interactivity in pharmaceutical 
R&D in Mexico.  
 
5. Determinants to PRO-industry interaction in pharmaceutical R&D in Mexico 
 
In Mexico low PRO-industry interactions reflect several reinforcing factors along a continuum. At a 
macro level the structure and functioning of the NSI is poorly conducive to such dynamic interactions, 
it characterizes by low investment in R&D, inadequate or limited research infrastructure. At a more 
disaggregated level, firms and PRO respond to different, somewhat difficult to conciliate incentives 
and aspirations; scientific communities face limited, even contradictory incentives to interact with 
firms. Figure 2 illustrates how determinants to interaction differ across different stages of the 
pharmaceutical R&D process. 
 
 
Figure 2. Determinants of interaction in pharmaceutical R&D in Mexico. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Santiago (2010) 
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The macroeconomic environment around STI in Mexico is poorly conducive to dynamic PRO-
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implementation, low incentives to R&D as the basis for successful business strategies, little 
interaction between relevant components of sectoral and NSIs, scarcity of human resources and 
inadequate research infrastructure (FCCT 2006). For more than a decade R&D expenditure has 
stagnated at around 0.40-0.46 per cent of GDP, somewhat below the 0.88 per cent recorded by Brazil, 
the largest economy and pharmaceutical market in Latin America (CONACYT 2007). Public 
investment in STI is also equivalent to only 0.36 per cent of GDP.  
 
Notwithstanding all the above the prospects for health research are somewhat better than those of 
other activities; over the last eight years or so public expenditure in health-research grew at an 
average rate of 13.7 percent. Unfortunately stagnant total public expenditure results in trade-offs 
between expanding investment in health and reduced support to other sectors.4 The good news is the 
growing private expenditure in R&D. In 1997-2005 private investment increased at a pace of 19.0 
percent per annum; from a share of 16.9 percent in 1997, it reached 41.5 percent of total expenditure 
in R&D in 2005 (CONACYT 2007). 
 
The business environment in Mexico induces poor incentives to R&D in general, and for PRO-
industry interactions in particular (Secretaría de Salud 2005). FCCC (2006) reports the dearth of 
domestic demand for products with more substantial domestic technological content; local firms 
privilege import of technologies developed elsewhere. In the case of the pharmaceutical industry, 
firms frequently decry the aggressive liberalisation and deregulation of the sector without 
accompanying policies to support development of the industry; firms face predatory behaviours from 
the public sector resulting from price controls, inconsistent application of IPR laws or public 
procurement mechanisms that privilege price over quality (Firms 02, 03, 04, 05, 06, 10 and 11). 
Related to this is the concentration of sales by domestic firms in the low price, high volume public 
sector; sales revenue hardly sustain enhanced in-house technological efforts (Firms 01, 03, 06 and 11). 
 
External demand as driver of local technological efforts remains insufficiently exploited. Hikino and 
Amsdem (1994) and Kim (1997) documented the key role played by export oriented business 
strategies for the successful catching up of some dynamic firms in South East Asia. Kim et al, (1989) 
noted similar experiences in pharmaceutical firms. In Mexico exports, particularly to the large US 
market, remain insufficiently exploited to strategically support technological progress by local 
pharmaceutical firms (Firms 03, 06, 12 and 14). To a large extent such passive behaviour reflects high 
                                                 
4 See FCCT (2006) and Dutrénit et.al., (2010) for a more ample discussion about the characteristics of 
expenditure in S&T in Mexico. 
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cost to obtain marketing licenses in the US,5 insufficient manufacturing capacity and limited R&D 
(Trade1). The limited export orientation of Mexican pharmaceuticals contrasts significantly with that 
of some of the larger Indian firms: “...the US market is such that you have to continuously keep 
launching the products to be able to compete and to retain your place in the market. You cannot 
launch four products and then sleep for the next one year, you have to continuously launch 10, 15 new 
products in a year. It requires a whole lot of commitment of resources, but also the company has to be 
geared towards servicing the market. And the Mexican companies so far, you know, they are pretty 
comfortable in Mexico; and to be able to service the more dynamic US generic market, I don’t think 
they have the mindset yet” (Firm12). 
 
Foreign firms induce limited incentives for domestic R&D: Mexico hosts affiliates of large 
multinationals from countries with long tradition in pharmaceutical innovation, namely the US, 
Germany, Switzerland and France; the country increasingly attracts affiliates from such new players 
as Spain and India as well. Multinational operations range from purely commercial to large-scale 
manufacturing and some R&D with distinct degrees of sophistication. Multinationals respond for the 
highest levels of modernisation and automation of the local industry. By contrast drug discovery is 
exceptional to nil; R&D concentrates in formulation, new applications or niche products tailored to 
the local market (Firms 01, 03, 07, 13, 17, 18, 20 and 21). Multinationals increasingly perform clinical 
research partnering with local research organisations, mainly public hospitals (Firms 03, 07, 13, 17, 
18, 20 and 21; Trade2; InsH1 and InsH3). Santiago (2009) indicates that relocation of clinical 
research reflects strategies intended to exploit country specific characteristics such as population size, 
epidemiological profiles and high prevalence of diseases affecting both developed and developing 
countries. Unfortunately relocation of R&D into developing countries seldom translates into enhanced 
dynamism by local innovative activities.  
 
Researchers and businessmen have distinct understanding of PRO-industry interactions. In the 
pharmaceutical industry PRO-industry interactions respond to two types of factors: On the one hand 
there is insufficient awareness and mutual understanding of the activities performed by both firms or 
PRO researchers, and the benefits of potential partnerships (Firms 05 and 06; Dutrenit et al, 2010). 
Arza and Vazquez (2008) report similar findings in Argentina. On the other hand there is uncertainty 
on the extent to which PRO-industry linkages increase the likelihood of succeeding in innovation. 
Eom and Lee (2008) assert that a large part of the knowledge from universities is intangible with 
uncertain impact on success in innovation.  
                                                 
5 Licenses to manufacture drug in the US are costly, costs vary depending on whether the product is innovator or 
generic; in other cases bails and insurances on compliance can be involved (Secretaría de Salud. 2005). Rights 
to manufacture serve effectively as entry barriers. 
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Firms and PRO look at STI through different eyes; both agents face different incentives and 
motivations, publish or perish clashes with time to market incentives and rewards (Firms 05, 06 and 
11). This is the classic dichotomy widely documented in the literature (Pavitt 1998; Stephan 1996; 
Stephan and Audrestsch 2000). In Mexico debate exists about the adequacy of incentives for 
researchers to work towards applied research, to take patents or develop new products in connection 
with firms (AMC-FCCT 2005); researches frequently ignore potential benefits of doing so (Firm 05 
and Trade2). Researchers benefiting from public programmes such as the SNI, primarily seek 
publication in international scientific journals and citations as core curricular activities (AMC-FCCT 
2005). Some recent measures in the fields of health sciences grant increased importance to 
technological developments-patents, prototypes, specialised software, technical reports, industrial 
secrets, copyrights, and so on, as valid products supporting promotion within the SNI (Secretaría de 
Salud, 2005).  
 
The perception of value of PRO-industry interactions differs across the research community; this 
complicates PRO-industry linkages. Researchers whose work orient to applied research or technology 
development, tend to interact more with firms, although interactions in basic science are not 
negligible (Dutrénit, et al., 2010). Whereas firms perceive universities mostly as sources of qualified 
human resources, the main role of public research centres is that of using R&D to solve concrete 
problems. By contrast PRO researchers see themselves as important knowledge generators for firms. 
Casas (2001 and 2005) indicate that firms in Mexico believe that they possess enough R&D 
capacities; hence they are not particularly pressed to seek external knowledge. In the spirit of Cohen 
and Levinthal (1989 and 1990) limited absorptive capacities complicate the identification and use of 
external knowledge.  
 
5.2.  Determinants of PRO-industry interaction across stages of the R&D process 
 
This paper argues that the nature and to a certain extent, the importance of determinants of PRO-
industry interactions vary along the different stages of the innovation cycle of an industry. Such 
different stages involve distinct kinds of agents, activities and knowledge flows; they require 
diversified skills, professional backgrounds, performance indicators and so on (Henderson and 
Cockburn 1994; Omta et.al, 1997). In the case of pharmaceutical innovation, different managerial 
approaches support drug discovery on the one hand, and drug development on the other (Chiesa 
1996). Research characterizes by unpredictable timing, informality in the structure of work, modes of 
expenditure and uncertain results. By contrast Development features more predictable timing to 
conclude tasks, formality in the organisation and conduction of activities, considerably larger 
expenditure and planned results (Chiesa 1996). Whereas key in research is “creativity”, key in 
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development is “organisation”; furthermore research and development split in both organisational and 
physical terms (Chiesa 1996). While firms conduct clinical research in connection with PROs, drug 
development, particularly generics, occurs mostly in-house with little reliance on PROs.  
 
The following paragraphs explore how determinants of PRO-industry interactions differ across the 
several stages of the pharmaceutical R&D process described in figure 1; the focus here is on a 
developing country such as Mexico. The analysis distinguishes between (1) basic research; (2) clinical 
research and (3) development of generics drugs and related process innovations. The analysis 
identifies factors that, according to interviews, affect with particular strength PRO-industry 
interactions for pharmaceutical R&D. 
 
5.2.1. Basic research 
 
Mexico possesses facilities to perform new drug-related research; yet activity in that area is incipient. 
Basic research takes place mostly at PRO with limited links to the industry. Why firms do not 
capitalise on those activities?  
 
Mexico integrates as manufacturing centre within the global strategy of pharmaceutical firms. In line 
with literature on internationalization of R&D (von Zedtwitz and Gassmann 2002), and from a 
business strategy view point, multinationals look at Mexico as a manufacturing location and 
consumption market more than as an R&D centre. Mexico lacks technical infrastructure, adequate 
regulatory frameworks around health-research and a critical mass of human resources sufficiently 
experienced in drug-related R&D (Firms 01, 02, 06, 13, Trade1, InsH1). A few public research 
centres meet world-class standards and possess adequate research methodologies and procedures, but 
this is insufficient to attract larger investments in R&D (Firms 01, 05 and 06). PRO lack sufficient 
equipment (i.e. column chromatography), in both the numbers and degree of sophistication required 
to, often simultaneously, carry out the massive amount of biological and chemical testings 
underpinning new drug discovery.  
 
The director of research at Firm 13 pointed out: “[The] Tests [we carry out] often should run 
simultaneously and at considerable precision and speed. [Mexican researchers have little or no 
experience in] conducting lead discovery projects, in understanding the physicochemical structure of 
the processes under research; for instance, to test for systemic or crossed effects of lead targets, 
particularly when processes of hypothesis testing involve combinations or simultaneous analysis of 
different molecules or substances”. Whereas R&D in a majority of Mexican firms strides to ensure 
interchangeability of generics products, multinationals are “exploring, testing and solving new 
hypotheses” (Firm 13). The regulatory environment complicates the obtaining of permissions to 
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transport, sometimes hazardous materials and samples for subsequent testing in new drug related 
research (Firms 13 and Trade2).  
 
According to Zúñiga and Combe (2002) it is difficult to expect significant increases in R&D 
expenditure by multinational pharmaceuticals in developing countries. Notwithstanding patent 
reforms, multinationals maintain their traditional concentration of corporate R&D laboratories in their 
parent countries. Additional, complementary factors are needed to attract research facilities into 
Mexico, including: (i) more coherent STI policies; (ii) better linking public research to specific health 
challenges and epidemic profiles of the Mexican population; (iii) direct promotion of pharmaceutical 
R&D; and (iv) raising quality standards of PROs’ infrastructure and staff.  
 
Inadequate processes and regulations for the definition and handling of intellectual property rights 
(IPR’s) at PRO hinders access to research with potential pharmaceutical use. It is problematic to 
negotiate technology transfer or joint development projects when no one owns the technology (Firms 
04, 06 and 13, trade1 and Trade2). Equally problematic is to value potential technologies; both 
researchers and businessmen find difficult to agree on faire prizes and distribution of eventual benefits 
stemming from new pharmaceutical products (Firms 05 and 06). According to firms, scientists think 
their work has potential to turn into something of great value and ask sizable compensations in return 
for whatever knowledge they share with firms (Firms 03 and 05). The opposite works too, with 
researchers’ complaints about the low value firms tend to grant to potential profitable scientific 
discoveries (InsH3).6  
 
The sectoral system of innovation underpinning pharmaceutical R&D is fragmented. Limited 
interactivity for pharmaceutical R&D in Mexico occurs between firms and research organizations, but 
also among PRO researchers and between these and other government institutions. For instance, the 
leader of the R&D department at Firm 13 commented that “Although diabetes is one of the most 
prevalent diseases in Mexico, so far there are no specific mechanisms whereby public health and S&T 
organisms, healthcare institutions, research organisations and firms can join forces to develop new 
drugs or other products for such population. Everybody is working on his/her own agenda without 
proper assessment of how research results may be applied and translated into new products”. Firms 
03, 05 and 06 supported this argument by noting the little interaction among firms in the industry in 
order to innovate. Firms find real difficulties to identify suitable partners and to build proper niches to 
                                                 
6 In this line Dutrénit, De Fuentes and Torres (2010) found that interactions through patents negatively affect 
intellectual benefits that Mexican researchers perceive from this form of interaction. Efforts to link through 
patents seem to greatly exceed the benefits obtained from them.  
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develop proprietary technologies; clearly a symptom of low in-house technological capacities (Cohen 
and Levinthal 1989 and 1990).  
 
Firms and PRO researchers have distinct strategic orientations. Pharmaceutical firms sponsor 
relatively little research projects at PRO. An additional point of contact is via awards and 
recognitions, through organisations such as CANIFARMA, to interesting basic research projects in 
the areas of health, medicine and pharmacology. In general however such projects seldom make it to 
the development stage; researchers are not interested in pursuing further development, applications 
are not immediately obvious or linkages with the industry fail to prosper (Firms 05, 11 and Trade1). 
According to Trade1 between 2000 and 2006 some 160 projects registered to the CANIFARMA 
Award in health and pharmaceutical-related research, with around eight projects obtaining the award. 
Of those successful projects no more than two have eventually transformed into tangible products. 
Trade1 mentioned negotiations between CANIFARMA and CONACYT to design awards in support 
of joint PRO-industry research, together with strategies to create critical masses of projects, mobilize 
resources and complementary assets from distinct research organizations.  
 
In the case of biotechnology Bolívar (1997) reported that in Mexico a major obstacle to develop 
industrial applications was the strong teaching or research orientation of graduate programmes in the 
field; they have little or no connection at all with industry needs. Firm 05 indicated that such problems 
persist; it stressed the “inadequate interpretation of the concept of biotechnology by Mexican policy 
makers. Because authorities take it as a generic sector, they tend to ignore differences in the 
development of applications for agriculture, food and pharmaceutical industries”. The research 
director of Firm 3 took further this argument by stressing the mismatch in the technological 
specialization of firms and universities in Mexico; whereas the former focus on biopharmaceutical 
applications, the latter focus mostly on applications in agriculture. Such divergence reduces the scope 
of interaction both in training, particularly at tertiary level, and actual research (Firm 05).  
 
Interviewees equally decried the uncertainty about whether large manufacturers of innovative 
products would willingly commercialise APIs developed by Mexican drug manufacturers (Secretaría 
de Salud 2005 and Firms 03 and 06). As noted by Hobday et. al., (2004) in the case of South Korea, 
catching up is problematic whenever latecomer firms fear entering into competition with their 
traditional input suppliers. Additional restrictions result from regulations that limit the capacity of 
PRO to receive funding and equipment from private organisations (Firm 6; InsH2), little linkages 
between public scholarship programmes and real needs for human resources in the industry (InsH1 
and Firm 06), insufficient funding for R&D, and the long time and high uncertainty inherent of 
pharmaceutical R&D (Secretaría de Salud 2005; Trade2).  
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5.2.2. Clinical research  
 
Firms’ strategies, research infrastructure and the regulatory environment: The length and high cost 
of clinical trials compel pharmaceutical firms to seek enhanced speed, coordination, efficiency and 
accuracy of those activities; firms aim to reduce time-to-market, increase profits and enhance product 
quality. Internationalization and concurrent performance of trials in multiple locations assist such 
goals. Developing countries such as Mexico increasingly contribute to drug development via the off-
shoring and outsourcing of clinical trials. Santiago (2009) notes that multinationals benefit from the 
presence of some world-class healthcare and research organisations in developing countries. Those 
organisations offer experience in conducting clinical research and in dealing with internationally 
acceptable practices governing clinical research. The later include ethics committees responsible to 
ensure that research protocols proceed in relatively efficient, ethical, transparent and speedy manner. 
Equally relevant is the nature of regulatory environments and availability of researchers with 
sufficient experience in the conduction of clinical research (Trade2, Insh2, Insh3 and CRO). 
 
Mexico is an attractive site for clinical research (Santiago 2009; Firm2; Trade2), it is a leading site in 
Latin America. In 2005 alone research protocols spanned more than 20 therapeutic areas and involved 
more than 1,000 institutions and 43,000 patients (AMIIF). By linking to PRO both foreign and 
domestic firms avoid the need to create specialized centres, as required by Mexican authorities, to 
perform clinical trials. Public health and research organisations grant access to large and captive 
segments of population under fairly standardized research conditions; IMSS host 70-80 percent of 
research protocols in Mexico (InsH2 and Trade2).  
 
Notwithstanding all the above, in Mexico the development of human resources required to further 
growth of clinical research lags behind the dynamics of local markets for those activities 
(LamtechInstitute 2007). There is also the need to improve regulatory frameworks in order to 
accommodate the distinct scientific content, risk profiles and other technical characteristics of clinical 
research, galenic developments and, in general, research involving direct testing of substances into 
humans (Firm05, InsH3, Trade1 and Trade2).  
 
The role of ethics as determinant of PRO-industry interactions remains insufficiently explored in the 
innovation literature; this is of great relevance in the case of clinical research. A look at the operation 
of ethics committees in Mexico, and the relationships between researchers in the public health system 
and private firms illustrate this argument.  
 
Similar to other countries, in Mexico performance of clinical research is governed, in part, by 
institutional review boards (IRBs) or ethics committees attached to the organisation hosting the 
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research protocol. IRBs are independent groups of people formally designated to approve, monitor 
and review biomedical and behavioural research involving humans; the aim is to protect the rights and 
welfare of voluntary study subjects. In Mexico notable barriers to PRO-industry interactions result 
from deficient conformation of IRB’s, excessive bureaucratic procedures, lack of coordination and 
duplication of responsibilities, even contradictory decision-making within public hospitals. For 
example Trade1, Firm01 and InsH2 decried contradictory resolutions in approval and funding 
mechanisms between the central research management at IMSS, and the IRBs at local hospitals of the 
same institute.7 Poor coordination delays regulatory approval of research protocols and increases 
uncertainty and overall transaction costs for the firm (Trade1 and Trade2).  
 
Ethics influences trust and thereby a researcher’s perception about the adequacy of linking with 
pharmaceutical firms; concerns are strong as “unethical” behaviours in the industry do happen 
(Santiago 2010b). Blumenthal (2004:1886) identify some such behaviours involving physicians and 
drug companies from “the seemingly trivial (e.g. the ubiquitous dispensing of gifts, such as pens and 
pads with drug names inscribed) to the much more troubling (e.g. the ghost-writing of articles for 
academic physicians, the payment of large honoraria and consulting fees to prominent physicians who 
extol the virtues of company products, and the support of lavish trips and entertainment for physicians 
who commonly prescribe company products).” Firm 05, InsH1, InsH2 and InsH3 coincided that some 
of the aforementioned practices occur in Mexico; suspicion and controversy around PRO-industry 
relationships hinder collaboration, or at least, the likelihood to openly report interactions (InsH1 and 
InsH2). Greater concerns refer to medical doctors that conduct clinical research outside the public 
research and health systems, respectively. Observance to self-imposed industry ethical codes of 
conduct is also problematic (Gómez, 2009).  
 
Is clinical research intellectually challenging and rewarding? Additional constrains for Mexican 
researchers to link with pharmaceutical firms result from the perception that such interactions are 
insufficiently challenging from an intellectual viewpoint. Multinationals reserve the design of clinical 
research protocols to staff at the parent location (Firms 01 and 07). Researchers in public hospitals 
and related organisations in Mexico can feel exploited (InsH2 and firm 05); or merely required to 
follow directions from sponsoring companies (CRO and InsH2). This reduces incentives to 
collaborate as participation in clinical trials is like doing “maquila”8 of research (InsH1). 
 
                                                 
7 IMSS is the main locus for new-drug related clinical trials in Mexico. 
8 The term “maquila” is borrowed from manufacturing activities denoting purely assembly, low value added, 
routinely activities performed by line-workers.  
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Global pharmaceutical firms approach product development assuming that drugs would be marketed 
in different locations throughout the world. Accordingly research protocols usually consider the 
specific physical and socio-economic conditions of all those different regions (Firms 01 and 13). Such 
vision is seldom shared by researchers who are not customarily exposed to the requirements of 
distinct regional markets for pharmaceutical products (Firms 9, 10, 11, 13 and Trade1).  
 
5.2.3. Drug manufacturing and development of generic drugs  
 
Pharmaceutical firms can be characterized according to the type of intellectual property rights they 
rely on. “Innovator companies” specialize in the development and manufacturing of innovative 
products protected by patents, while generic manufacturers produce drugs whose patent has already 
expired. Finally there are firms that participate in both markets (Santiago 2010). Pharmaceuticals in 
Mexico specialize in the manufacturing of generic drugs. Accordingly the subsequent analysis focuses 
on factors determining PRO-industry interaction in relation to generics drugs development and 
innovations in drug manufacturing processes.  
 
In Mexico, development of generics drugs starts three to four years before patent expiry of the 
innovator product; the goal is to reproduce the knowledge behind the innovative drug while ensuring 
bioequivalence and bioavailability of the generic drug. In most cases, the choice of products considers 
current product portfolios; what firms already know. Nevertheless expected benefits increase if firms 
can enhance the characteristics of the innovator drug; this includes relatively simple improvements in 
product packaging, reformulation or recombination of existing molecules. By contrast, new products 
include new applications of existing drugs, often in different therapeutic areas. The search for new 
knowledge often relates more to the methods and techniques to synthesize the components---
biotechnology---than to the characteristics of the drug itself (Kale and Little 2007). 
 
PRO and firms face distinct levels of technological attainment. Table 1 revealed the limited PRO-
industry interaction for process innovations in the pharmaceutical industry. This reflects the 
disconnection between the scientific and technological capabilities of firms and PRO in Mexico. 
Firms focus on the development of generics drugs, while PRO seek to advancing the technological 
frontier (Firms 03, 06 and 11). Firms rely strongly on in-house knowledge sources, or on external 
suppliers, particularly APIs, to find technological solutions (Firms 05 and 06). By contrast PRO 
researchers perceive as insufficiently challenging to work on projects that do not result in publications 
or outstanding scientific findings (Firms 03 and 05; InsH1, InsH3). Selective reporting of research 
results according to commercial interests vitiates incentives for PRO-industry interactions (InsH1).  
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Pharmaceutical firms need to ensure that drug manufacturing processes meet strict standards of 
quality and safety for human consumption; in practice this leads to adoption of internationally 
accepted Good Manufacturing Practices.9 According to businessmen, Mexican researchers often fail 
to fully appreciate these several legal procedures required to test, develop, escalate, manufacture and 
market (new) drugs (Firm 05 and Trade2). Development of potential new drugs requires time, 
considerable financial resources, advanced and properly certified facilities including laboratories, 
pilot plants and personnel; these are not always available at Mexican PRO (Firms 04, 05, 06, 12 and 
13 and Trade2). Strategies to overcome the aforementioned limitations are diverse. Firms 04 and 06 
reported to have invested in laboratory equipment and manufacturing infrastructure inside PRO. 
Whereas the former firm gained access to basic research facilities and interaction with PRO staff, the 
latter developed an exclusive API supplier. These strategies promote knowledge transfer, and help 
PROs to learn about the best laboratory and manufacturing practices required by the industry.  
 
Casas (2001) indicated that training is one of the main reasons for PRO-industry interactions in 
Mexico; however PRO often fail to meet industry’s requirements. Both Mexican and multinational 
firms decried the lack of adequate infrastructure at universities: “it is hard to replicate and learn about 
the most modern synthesis and analytical techniques, manufacturing and laboratory practices used by 
the industry” (Firm 03). Lack of “faculty with sufficient experience and understanding of the 
industry” (Firm 03), (exacerbates) difficulties to observe confidentiality requirements of firms (Firms 
03 and 06). Learning through interactions with input suppliers tend to be more important for the firm 
(Firms 03, 05, 06, 07).  
 
The use of public procurement to induce demand for new pharmaceutical products with strong local 
content remains limited. Mexican health and industry authorities have abandoned public procurement 
as mechanism to promote development of the local pharmaceutical industry (Santiago 2010). Public 
tenders privilege prices over quality, local content, or market risks faced by suppliers (Firms 04, 05, 
06 and 10); arguably this distorts the market and reduces incentives to innovate (Firm 03, 05, 06, 07, 
11 and 14). The privilege on manufacturing scale and speed to market over quality effectively reduces 
the scope for PRO-industry interactions underpinning the design or improvement of products. Firms 
adopt survival strategies based more on the capacity to manufacture large volumes of generic 
products; they privilege automation and increased manufacturing capacity even if significant margins 
remain idle (Firm 03 and 05). 
                                                 
9 GMP’s cover layout and functionality of buildings, qualification and training of personnel, cleanliness and 
sanitation, monitoring, supervision and many other aspects, from beginning to the end, of drug manufacturing. 
GMP’s are constantly reviewed and adjusted according to scientific and technological advances. Regulatory 
agencies watch closely this requirement even by conducting physical inspections of productive facilities. 
23 
 
 
6. Discussion and concluding remarks 
 
Innovation scholars emphasize the key role of PRO-industry interactions for good performance of 
systems of innovation; interactivity brings together complementary assets, facilitates knowledge 
sharing, problem solving and the co-evolution of technological capabilities. Researchers devote 
significant efforts to understand determinants of PRO-industry interactions and their effects on the 
functioning of systems of innovation. Alternatively, the interest is in identifying the main actors and 
channels underpinning interactivity. This paper both contributes and extends this body of literature.  
 
This paper looked at determinants of PRO-industry interactions in Mexico who, similar to other 
developing countries, characterizes by limited interactivity and consequently, poor innovation 
performance. The paper asked what limits interactivity in developing system of innovation. Empirical 
evidence refers to the pharmaceutical industry in Mexico. The paper explored the socioeconomic 
context in which pharmaceutical firms operate, how the country contributes to pharmaceutical 
innovation, and the role PRO-industry interactions play in each stage of the pharmaceutical R&D 
process. Interactivity is of strategic importance, it helps firms to keep abreast of developments in 
(new) drug-related R&D. In Mexico this is not always possible as diverse components of the system 
of innovation remain fragmented, insufficiently connected or, in fact, non-existent. 
 
A key contribution to the literature resulted from the decomposition of the pharmaceutical innovation 
process; hence the analysis identified the different instances of the process, notably R&D. By 
proposing this type of approach the paper expands traditional studies centred on exploring where, 
when and how firms and PRO interact. It illustrates the pertinence to look beyond national and cross-
sector perspectives that fail to take fully into account the nature of innovation in specific industries. 
Arguably, such distinction influences the characteristics of PRO-industry. 
 
Decomposition of the pharmaceutical R&D process mirrored previous studies by Crossely (2004), 
Gassmann and von Zedtwitz (1999) and Chiesa (1996). The approach illustrated the complexity of the 
R&D process, identified the agents involved across those different stages and consequently, the 
diverse factors that either promote or hinder interactivity for pharmaceutical R&D.  
 
The paper showed that PRO-industry interactions depend on factors pertaining to the macroeconomic 
environment, the availability and quality of research infrastructure and human resources, and the 
structure of IPR regimes. Moreover the paper showed that the way in which all those factors interplay 
differs throughout the distinct stages of pharmaceutical R&D. Accordingly, strategies to improve 
research infrastructure and human resources, for instance, need to carefully consider the 
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characteristics of both the processes and the people involved in basic research-drug discovery-, as 
opposed to those contributing to clinical research–hypotheses testing-, or drug manufacturing-scaling 
of new drugs, chemical synthesis of existing drugs, or development of generics drugs.  
 
The paper substantiated the importance of the institutional environment as determinant of PRO-
industry interactions. IPR regimes, regulatory mechanism and notably, ethics of research involving 
humans influence differently PRO-industry interactions. Additional factors relate to the motivations, 
aspirations and mechanisms to evaluate, sanction and reward people involved in PRO-industry 
interactions. The structure of incentives accommodates both “short-sighted” businessmen and “ivory 
tower” academics as factors shaping PRO-industry interactions. Enhanced linkages require 
translators, facilitators that bring together scientific work and commercial interests. Adequate 
observance and enforcement of IPRs should accompany codes of practices respectful of the ethos of 
academic work. Both academics and businessmen need to be more open, willing to learn from and 
understand each other.  
 
In the aggregate a series of indirect and direct factors shape the scope and space for PRO-industry 
interactions underpinning pharmaceutical R&D. The macroeconomic environment around R&D, 
innovation more broadly defined, creates or suppresses the conditions for more active innovative 
behaviours of both PRO and domestic firms. The latter can miss opportunities to learn and innovate 
by taping into foreign direct investment and participation in export markets; business strategies geared 
mostly to survival narrow the space for sustained and more systematic in-house technological efforts. 
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Annex 1. General description of interviews carried out as part of this study 
 
Firm Origin Employment Sales1/ Years/2 interview Contact Duration/3 
01 Foreign 210 360000 <3 25/Jun/07 Director general 63 
02 Foreign 1100 3119745 >50 11/Jul/07 Plant manager  
     20/Mar/07 Supervisor Manufacturing 75 
     26/Mar/07 Staff Manufacturing 60 
03 Mexican n.a. 281775 >50 17/Jul/07 Plant manager 104 
     17/Jul/07 Development manager 81 
     17/Jul/07 Research director 88 
04 Mexican 421 n.a. ~30 02/Jul/07 CEO 31 
05 Mexican 343 450000 ~40 11/Jun/07 CEO 92 
     19/Jun/07 Plant manager 109 
06 Mexican n.a. 416394 ~40 07/May/07 Director General Development manager 110 
     04/Jul/07 Development manager & two staff members  
07 Foreign 808 2228675 ~40 02/Apr/07 Director General 34 
     10/Apr/07 Communications manager 55 
     16/Apr/07 Medical and regulatory affairs manager 32 
08 Foreign 1100 n.a. >50 16/Feb/07 Latin America, Human 
resource management 
affairs 
120 
     13/Mar/07 90 
     16/Mar/07 Technical operations 75 
09 Mexican n.a. n.a. >50 09/Mar/07 Former CEO assistant 60 
10 Mexican n.a. n.a. >50 07/Dec/07 Former Director General 76 
     16/Jul/07 Head R&D department 89 
11 Mexican 770 600000 +30 27/Jul/06 27/Feb/07 Operations director 
120 
75 
12 Foreign n.a. n.a. <4 11/Jul/07 Director General 19 
13 Foreign >1000 n.a. >50 30/Jul/07 R&D director 47 
     30/Apr/07 Development manager 31 
14 Mexican >1000 n.a. >50 23/Nov/07 R&D director 71 
15 Foreign >1000 4583905 >40 26/Jul/06 Human resource technician 60 
164/ Mexican >30 n.a. >20 19/10/07 Director general --- 
174/ Foreign >1000 n.a. >30 14/Aug/07 Medical director --- 
184/ Foreign >1000 n.a. >50 19/Aug/07 Communication director --- 
194/ Mexican >30 11000 >70 14/Aug/07 Director general --- 
204/ Foreign 90 n.a. 3 14/Aug/07 Operations director --- 
214/ Foreign >350 n.a. >70 14/Aug/07 Medical director --- 
224/ Mexican >40 n.a. 4 14/Nov/07 Director general --- 
Trade1 --- --- --- --- 26/Mar/07 Director research 100 
Trade2 --- --- --- --- 03/May/07 Director communications 52 
InsH1 --- --- --- --- 12/Jul/07 Coordination 23 
InsH2 --- --- --- --- 09/Oct/08 Research coordination 90 
InsH3 --- --- --- --- 18/Apr/07 Director 35 
CRO --- --- --- --- 04/Apr/07 Clinical research monitor 60 
Notes: 1/ thousand Mexican pesos; 2/ years of operation in Mexico; 3/ in minutes; 4/ correspond to firms that returned the 
interview instrument together with some comments; TradeX: Trade organization; InsHX: National Health Institute; IMSS or 
Regulatory body; CRO: Contract research organization; n.a. Not available because the firm denied the information or provided 
only the share of products/markets. 
Source: Author based on interviews  
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